

1 **Running title**

2 Neural Mechanosensitivity in Chronic Neck Pain.

3

4 **Title**

5 Differences in Neural Mechanosensitivity between Patients with Chronic
6 Nonspecific Neck Pain with and without Neuropathic Features. A Descriptive
7 Cross-Sectional Study.

8

9 **Authors**

10 Ibai López-de-Uralde-Villanueva, PT, MSc¹⁻⁴; Hector Beltran-Alacreu, PT, MSc¹⁻³;
11 Josué Fernández-Carnero, PT, PhD^{2,4,5}; Alfonso Gil-Martínez, PT, MSc¹⁻⁴; Roy La
12 Touche, PT, MSc¹⁻⁴.

13

14 **Institutions**

- 15 1. Department of Physiotherapy, Faculty of Health Science, The Center for
16 Advanced Studies University La Salle. Universidad Autónoma de Madrid,
17 Aravaca, Madrid, Spain.
- 18 2. Research Group on Movement and Behavioural Science and Study of Pain, The
19 Center for Advanced Studies University La Salle, Universidad Autónoma de
20 Madrid.
- 21 3. Institute of Neuroscience and Craniofacial Pain (INDCRAN), Madrid, Spain.
- 22 4. Hospital La Paz Institute for Health Research, IdiPAZ, Madrid, Spain.
- 23 5. Department of Physical Therapy, Occupational Therapy, Rehabilitation and
24 Physical Medicine, Universidad Rey Juan Carlos, Alcorcón, Madrid, Spain.

25

26 **DISCLOSURES**

27 **Acknowledgment of any presentation of this material:**

28 No presentation of this material before.

29 **Acknowledgment of financial support, including grant numbers:**

30 No financial support.

31 **Explanation of any conflicts of interest:**

32 No conflicts of interest.

33

34 **Corresponding author**

35 Ibai López-de-Uralde-Villanueva.

36 Faculty of Health Science.

37 The Center for Advanced Studies University La Salle. Universidad Autónoma.

38 Calle la Salle, 10.

39 28023 Madrid.

40 SPAIN.

41 Telephone number: + 34 91 7401980

42 Email address: ibai.uralde@gmail.com

43

44

45

46

47

48

49

50

51 **ABSTRACT**

52 **Objective:** To assess differences in neural mechanosensitivity between patients with
53 chronic nonspecific neck pain with and without neuropathic features (NF and No-NF,
54 respectively).

55 **Design:** Descriptive, cross-sectional study.

56 **Setting:** A primary care center, a hospital physiotherapy outpatient department, and a
57 university campus.

58 **Subjects:** Chronic nonspecific neck pain patients classified by the Self-completed
59 Leeds Assessment of Neuropathic Symptoms and Signs pain scale [S-LANSS; 49
60 patients with NF (S-LANSS \geq 12) and 50 patients with No-NF (S-LANSS $<$ 12)] and
61 a healthy control group (n = 48).

62 **Methods:** The primary measurements were the mechanosensitivity of the median
63 nerve and cervical region, specifically the assessment of the onset of symptoms and
64 submaximal pain intensity according to the Upper Limb Neural Test 1 (ULNT1) for
65 the median nerve and the Modified Passive Neck Flexion Test (MPNFT) for the
66 cervical region; secondary measurements included pain intensity, neck disability,
67 kinesiophobia, and pain catastrophizing.

68 **Results:** Statistically significant differences between the NF and No-NF groups were
69 found with respect to the onset of symptoms of ULNT1 [-15.11 (-23.19 to -7.03)] and
70 MPNFT [-6.58 (-11.54 to -1.62)], as well as the outcomes of the VAS [Mean
71 difference (95% Confidence Interval); 7.12 (1.81 to 12.42)] and NDI [3.72 (1.72 to
72 5.71)]. Both chronic nonspecific neck pain groups showed statistically significant
73 differences compared to the CG for all outcomes assessed (P<0.01) except for the
74 onset of symptoms of ULNT1 in the No-NF group.

75 **Conclusions:** The findings of this study suggest that chronic nonspecific neck pain
76 patients with NF have greater neural mechanosensitivity, pain intensity, and neck
77 disability than those with No-NF.

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99 **Key words:** chronic pain, mechanosensory, psychosocial factors, neck pain, pain
100 catastrophizing.

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124 INTRODUCTION

125 Neck pain is one of the most significant problems in healthcare [1]. With three-
126 quarters of people worldwide experience pain in this region at some time in their lives
127 [1], this condition has considerable social and economic impact [2,3]. In addition,
128 neck pain is more prevalent in middle-aged women and tends to become chronic
129 [4,5].

130

131 Nociceptive pain is defined as “pain that arises from actual or threatened damage to
132 non-neural tissue and is due to the activation of nociceptors” [6], while neuropathic
133 pain is defined as “pain caused by a lesion or disease of the somatosensory nervous
134 system” [6,7]. Conceptually, in neuropathic pain, the excitability of neurons increases
135 as a result of sensitization. Nowadays there is a debate about whether this
136 sensitization occurs in the peripheral or central nervous systems or both [8]. It is also
137 unclear whether chronic neck pain is a neuropathic or nociceptive [9]. A sensory
138 hypersensitivity can be considered a dysfunction of the nervous system [10]. A
139 cervical hypersensitivity has been demonstrated in chronic neck pain conditions, but
140 the existence of a widespread hypersensitivity is still debated. The widespread
141 hypersensitivity in chronic whiplash is supported by several investigations [11–15];
142 however, in chronic nonspecific neck pain the literature is limited and controversial
143 [13,16–19]. Some research has shown that whiplash may have a neuropathic features
144 (NF) [12,20,21], which could explain the difference in the pain processing mechanism
145 found with chronic nonspecific neck pain. In addition, patients with whiplash have a
146 higher neural mechanosensitivity in the upper limb nerve trunks in neurodynamic
147 tests [21,22], potentially contributing to the appearance and perpetuation of
148 widespread hypersensitivity. However, there is a lack of evidence regarding the neural

149 mechanosensitivity in chronic nonspecific neck pain. The neural mechanosensitivity
150 is believed to be a protective mechanism that occurs when nerves are subjected to
151 mechanical stress during movement [23]. Hence, considering the information
152 presented above, it is possible that patients with chronic nonspecific neck pain with
153 NF will present higher neural mechanosensitivity than those without NF (No-NF).

154

155 In the literature, several authors consider the classification of nociceptive pain and
156 neuropathic pain as relatively simple; however, this organization is useful for
157 selecting the optimal treatment for reducing pain [10,24–27]. Among the diverse tools
158 to discern between the two types of pain, the Self-completed Leeds Assessment of
159 Neuropathic Symptoms and Signs (S-LANSS) score is a reliable and valid tool for the
160 differential diagnosis of pain with NF [28].

161

162 There are studies that suggest psychological factors influence the results of neural
163 tests [29–31]. Beneciuk et al. [29] reported that asymptomatic subjects with more pain
164 catastrophizing experience a more intense pain when undergoing the Upper Limb
165 Neural Test 1 (ULNT1), while the elbow's range of motion did not show any
166 correlation. This test is often used as a diagnostic tool in patients with neurogenic
167 symptoms in the upper limb [32], allowing us to assess the median nerve and the
168 brachial plexus mechanosensitivity [33,34]. Therefore, our hypothesis is that chronic
169 nonspecific neck pain patients with NF will present greater mechanosensitivity than
170 those with No-NF when the neural test is applied.

171

172 Thus, the aim of our study was to assess differences present in patients with chronic
173 nonspecific neck pain regarding neural mechanosensitivity of the upper limb and

174 cervical region comparing those with NF and those with No-NF. In addition, the
175 authors expected to observe associations in these two types of chronic nonspecific
176 neck pain between neurodynamic test outcomes and psychosocial factors.

177

178 **METHODS**

179 **Study Design and Raters**

180 A cross-sectional study was conducted to assess differences in the neural
181 mechanosensitivity of patients with chronic nonspecific neck pain with NF compared
182 to patients with chronic nonspecific neck pain with No-NF. The investigation was
183 developed according to the Strengthening the Reporting of Observational studies in
184 Epidemiology (STROBE) statement at the beginning of November 2011, being
185 finished in March 2014.

186

187 The research team was composed of 4 clinical examiners (6, 6, 8 and 10 years post
188 qualification experience) with over 5 years of experience in manual therapy. Two
189 half-hour training sessions were scheduled to perform the neurodynamic test in a like
190 manner before commencing the actual study; in order to ensure this objective, all
191 examiners performed the tests several times and followed a standardized sequence for
192 each neurodynamic test (See “Mechanosensitivity of the Median Nerve and the
193 Cervical Region” section). This procedure was continued until all examiners
194 performed both test the same way. Additionally, they were responsible for collecting
195 all outcome data, so it was an unblinded study.

196

197 **Subjects**

198 A total of 147 subjects were recruited for the study. The control group (CG) consisted
199 of 33 females and 15 males (mean \pm SD age, 43.64 ± 11.09) recruited from the Center
200 for Advanced Studies University La Salle (Madrid, Spain) by print advertisements
201 placed around the campus. All of the subjects in this group were between 18-65 years
202 old and received a physical assessment to confirm their pain-free state. The CG
203 exclusion criteria were as follows: 1) history of cervical, upper limb, orofacial, or
204 upper thoracic pain in the previous 12 months; 2) previous cervical surgery and/or
205 whiplash trauma; and 3) taking any medication during the last 3 months.

206

207 Patients with chronic nonspecific neck pain were consecutively recruited by referral
208 from the primary care center of Coslada (Madrid) and the physiotherapy outpatient
209 department of University Hospital La Paz (Madrid). These patients were classified by
210 the S-LANSS. The final sample was constituted of 49 patients (41 females y 8 males;
211 42.38 ± 14.26) with NF (NF; S-LANSS ≥ 12), and 50 patients (37 females y 13
212 males; 44.76 ± 14.66) with No-NF (No-NF; S-LANSS < 12). The symptomatic
213 subjects were selected if they fulfilled the following inclusion criteria: age between
214 18-65 years; neck/shoulder pain for at least 3 months with symptoms provoked by
215 neck postures, neck movement, or palpation of the cervical musculature; clinical
216 diagnosis of nonspecific neck pain by a medical specialist; and the ability to read and
217 speak Spanish. Patients were also excluded if they presented rheumatologic diseases
218 or any type of cancer, cervical surgery in the past, cervical radiculopathy,
219 myelopathy, whiplash trauma, or if they had received some type of pain treatment,
220 including medication and physical therapy, during the last 3 months.

221

222 After checking that each of the subjects met the inclusion/exclusion criteria, all
223 participants were asked to read and sign informed consent approved by the local
224 Ethics Committee for Clinical Research of the Hospital La Paz (registration number:
225 PI-1241).

226

227 **Dependent Outcome.**

228 The S-LANSS was used to identify pain with NF. The application of this scale is
229 comprised of two phases. The first consisted of 5 questions that the patient should
230 answer "yes" if they are related to the pain that they suffered during the last week.

231 The second phase contained two questions for which patients had to examine
232 themselves to determine the presence of allodynia and altered sensation. These items
233 are marked as present or absent with appropriate scale scores. The assessor is then
234 asked to sum the scale scores and compare them with the cut-off values ("if score \geq
235 12, then neuropathic mechanisms are likely to contribute to the patient's pain") [35].

236 The S-LANSS is a modified version of the LANSS scale. The LANSS scale consists
237 of 7 similar questions, two of which include clinical examination by a physician to
238 determine the presence of allodynia and altered pinprick threshold. Thus, the
239 difference between these two scales is that the S-LANSS is a self-administered
240 questionnaire, whereas the LANSS requires physician examination. The original S-
241 LANSS scale has proven to be a reliable and valid instrument for the differential
242 diagnosis of pain with NF [28]. In the absence of a Spanish version of the S-LANSS,
243 we translated the original scale using a translation/back-translation process, following
244 the classic procedure [36]. As a measure of the internal consistency, we used
245 Cronbach's alpha, which was determined to be 0.72.

246

247 **Primary Measurements**

248 **Mechanosensitivity of the Median Nerve and the Cervical Region**

249 These outcomes were assessed using the following neurodynamic tests: ULNT1 and
250 Modified Passive Neck Flexion Test (MPNFT) (Figure 1). Below, the authors briefly
251 describe what each test consisted of and its purpose:

252

253 *ULNT1*

254 This test was used to assess the mechanosensitivity of the median nerve. To perform
255 the test, all subjects were asked to lie supine. The examiner then placed one of the
256 heads of an ACUMAR digital dual inclinometer (Model ACU 002 from Lafayette
257 Instrument Company; Lafayette, Indiana) at the midpoint of the dominant arm and the
258 other in the distal third of the forearm. Both heads were fixed by means of Velcro
259 strips. According to manufacturer's specifications, this digital inclinometer is capable
260 of measuring -180° to $+180^{\circ}$ with an accuracy of ± 1 . The sequence used for ULNT1
261 was the following: depression of the shoulder girdle, shoulder abduction 90° , forearm
262 supination, wrist and finger extension, then shoulder external rotation. At this time,
263 the examiner reset the marker on the digital inclinometer. Finally, the examiner
264 proceeded to perform elbow extension. When the participant's symptoms started the
265 physiotherapist recorded the inclinometer's values (elbow extension range of motion).
266 Following this, the assessor continued to increase elbow extension until reaching the
267 submaximal pain of the subject (the greatest level of pain which the subject was
268 prepared to tolerate) and then asked the participant to indicate the amount of pain
269 perceived using the Visual Analogue Scale (VAS). The examiner performed 3
270 consecutive repetitions of the ULNT1 with 30 seconds between them. Due to the
271 parameters of shoulder depression and shoulder abduction, the ULNT-1 increases

272 strain throughout the brachial plexus [34]. Hence, the patient's symptoms must be
273 reproduced by the test due to its mechanical provocation in the cervical roots and
274 median nerve [37,38]. Hypersensitive responses to this test have been established in
275 chronic neck pain [39,40]. In addition, the ULNT1 is a reliable measure of median
276 nerve mechanosensitivity [Intraclass Correlation Coefficient (ICC) = 0.80; Standard
277 Error of Measurement (SEM) = 3.83°; Minimal Detectable Change (MDC) = 10.58°]
278 [41,42], and can be a valid tool to determine certain diseases such as cervical
279 radiculopathy [43,44].

280

281 *MPNFT*

282 The passive neck flexion test is used to diagnose possible spinal disorders, headaches,
283 and arm and leg pain with a cervical origin. It was used a modified version of this test
284 in which the subject was placed in the supine position with arms along the body, and
285 the simple digital inclinometer was attached to the frontal bone with Velcro strips.
286 The assessor performed two grasps: 1) on the occipital bone and 2) on the upper jaw
287 (just below the nose of the participant). Subsequently, the examiner made a double
288 chin movement (increasing the tension in the cranio-cervical area), followed by neck
289 flexion. At this point, the procedure used was the same as for the ULNT1; the
290 physiotherapist recorded the range of motion of appearance of symptoms, and the
291 pain intensity perceived by the subject on the VAS. The examiner performed 3
292 consecutive repetitions of the MPNFT with 30 seconds between them. In the absence
293 of reliability studies of the MPNFT, we used the 3 measurements obtained to assess
294 the reliability of the test (ICC = 0.81-0.91; SEM = 2.18-4.13°; MDC = 5.10-9.64°).

295

296 **Secondary Measurements**

297 Pain intensity was measured via the VAS. It was a 100-mm horizontal line with pain
298 descriptors marked “no pain” at the left side and “the worst pain imaginable” at the
299 right side. The patient was asked what their pain intensity was at the time by marking
300 the VAS with a perpendicular line. The VAS has been found to be a reliable and valid
301 measure of pain [45,46]. A difference of 11.1-mm in the VAS is considered the MDC
302 in patients with a chronic pain of moderate intensity (40-mm < VAS score < 70-mm)
303 [47].

304

305 Disability was assessed using the Neck Disability Index (NDI). It is a 10-item
306 questionnaire, with 6 possible answers that represent 6 levels of functional capacity,
307 ranging from 0 (no disability) to 5 (complete disability). Higher scores indicate more
308 disability (maximum score, 50 points). The NDI has sufficient support in the literature
309 to be the most commonly used method to report neck pain [48,49]. A validated
310 Spanish version of the NDI was used [50]. The MDC for the NDI is reported to be
311 approximately 5 points [48].

312

313 The abbreviated version of the Tampa Scale for Kinesiophobia-11 (TSK-11) was used
314 to assess fear of movement and injury. The validated Spanish version has shown good
315 reliability and validity [51]. The 11 items are scored 1-4, with total scores ranging
316 from 11 to 44. The addition of all the points obtained from each of the items results in
317 the level of kinesiophobia, with higher scores indicating greater perceived
318 kinesiophobia. The SEM and MDC for the TSK-11 were 2.41 and 5.6 points,
319 respectively [52].

320

321 To evaluate the participant's propensity to catastrophize about pain, it was used the
322 Pain Catastrophizing Scale (PCS). This tool is a 13-item questionnaire designed to
323 measure the three components of pain-related catastrophizing: rumination,
324 magnification, and helplessness, resulting in a unique score. Each item is responded to
325 on a 5-point scale (0 = not at all, 4 = all the time) relating the degree to which the
326 individual experiences a thought or feeling of a painful situation. The Spanish version
327 also showed appropriate psychometric properties [53].

328

329 **Sample Size**

330 The sample size was calculated by G*Power© 3.1.7 software (University of
331 Düsseldorf, Germany) [54] and was considered as a power calculation to detect
332 between-group differences in the primary outcome measures (Mechanosensitivity of
333 the Median Nerve and the Cervical Region). To obtain 90% statistical power (1- β
334 error probability) with an α error level probability of 0.05, a one-way fixed-effects
335 analysis of variance model and a medium-large effect-size of 0.3 were used; this
336 effect-size was established using a theoretical model based on a previous study [20].
337 It was estimated that at least 144 subjects would be required (48 per group).

338

339 **Data Analysis**

340 The statistical analyses were performed using Statistical Package for the Social
341 Sciences (SPSS) software version 20.0.^f (SPSS 21, SPSS Inc., Chicago, IL USA). For
342 all of the analyses, statistical significance was set at $P < 0.05$. The descriptive
343 statistics used to summarize the data for the continuous variables are presented as the
344 means \pm standard deviation (SD) and the 95% confidence interval (CI), whereas the
345 categorical variables are presented as an absolute number or relative frequency

346 percentage. For all of the variables, the Z-score was assumed to follow a normal
347 distribution based on the central limit theorem because all of the groups had more
348 than 30 subjects [55,56].

349

350 A chi-square test with residual analysis was used to compare the categorical variables.

351 One-way analysis of variance (ANOVA) was used to analyze the continuous

352 parametric data; the group factor was analyzed for primary and secondary

353 measurements (mechanosensitivity variables of the median nerve and the cervical

354 region; VAS; NDI; TSK-11; PCS). A post hoc analysis with Bonferroni corrections

355 was performed in the case of significant ANOVA findings for multiple comparisons

356 between variables. To test the relationship between neurodynamic test outcomes and

357 psychosocial variables, Pearson's correlations were calculated separately for pain

358 with NF, pain with No-NF and CG.

359

360 Multiple linear regression analysis was performed to estimate the strength of the

361 associations between the results of the mechanosensitivity outcomes of the median

362 nerve and the cervical region (criterion variables) in the two chronic nonspecific neck

363 pain groups (NF and No-NF). The psychological and pain-related variables (TSK-11,

364 PCS, VAS, and NDI) were used as predictor variables.

365

366 The variance inflation factors (VIFs) were calculated to determine whether there were

367 any multi-collinearity issues in any of the three models. The strength of association

368 was examined using regression coefficients (B), P values, and adjusted R^2 . The

369 standardized beta coefficients (β) were reported for each predictor variable included

370 in the final reduced models to allow for direct comparison between the predictor

371 variables in the regression model and the criterion variable being studied. For the
372 regression analysis, the rule of 10 cases per variable was applied to obtain reasonably
373 stable estimates of the regression coefficients [57].

374

375 **RESULTS**

376 A total of 154 chronic nonspecific neck pain patients were screened, of whom 147
377 (95.5 %) were eligible and agreed to enter the study. The mean age of the sample was
378 43.63 ± 13.41 years and most of them were female (75.5%). Regarding the duration
379 of neck pain, the NF group reported an average of 83.8 ± 66.16 months (range, 6-300;
380 95%CI, 64.79 to 102.8), while the No-NF group reported 84.08 ± 89.53 months
381 (range, 4-360; 95% CI, 58.9 to 109.26). No differences were found between the 3
382 groups for the demographic characteristics; thus, the groups were similar and
383 comparables. Further descriptive characteristics of the participants are shown in Table
384 1.

385

386 The results of the ANOVA revealed a significant effect for the Group factor [onset of
387 symptoms of ULNT1 ($F = 24.188$; $P < 0.001$); submaximal pain intensity reported in
388 ULNT1 ($F = 22.346$; $P < 0.001$); onset of symptoms of MPNFT ($F = 31.311$; $P <$
389 0.001); submaximal pain intensity reported in MPNFT ($F = 126.136$; $P < 0.001$); VAS
390 ($F = 428.717$ $P < 0.001$); NDI ($F = 187.755$; $P < 0.001$); TSK-11 ($F = 31.492$; $P <$
391 0.001); PCS ($F = 28.200$ $P < 0.001$)]. Statistically significant differences between the
392 NF group and No-NF group were found with respect to the onset of symptoms of
393 ULNT1 and MPNFT, as well as the outcomes of the VAS and NDI. Both chronic
394 nonspecific neck pain groups showed statistically significant differences compared
395 with the CG for all outcomes assessed except the onset of symptoms in the ULNT1

396 for the No-NF group. Table 2 shows the values as mean \pm SD of each group and mean
397 differences (95% Confidence Interval) between groups.

398

399 The authors examined the association (Pearson correlation coefficients) among the
400 mechanosensitivity variables of the median nerve and the cervical region, VAS, NDI,
401 TSK-11, and PCS against themselves for each group (Table 3). The largest
402 association observed in the NF group ($r = -0.733$; $P < 0.001$) and the CG ($r = -0.617$;
403 $P < 0.001$), was between the onset of symptoms of ULNT1 and submaximal pain
404 intensity reported in the same neural test, while in the No-NF group was between
405 submaximal pain intensities reported in both neural tests ($r = 0.601$; $P < 0.001$).

406

407 The regression models for criterion variables (mechanosensitivity of the median nerve
408 and the cervical region) are presented in Tables 4 and 5. The regression model for the
409 NF group showed that only TSK-11 was a significant predictor of the onset of
410 symptoms of ULNT1 (19% of variance), while VAS was a significant predictor of the
411 onset of symptoms of MPNFT (28% of variance). For this same group, the significant
412 predictor variables of submaximal pain intensity reported in ULNT1 and MPNFT
413 were PCS (25.9% of variance) and NDI (9.8% of variance), respectively. In the No-
414 NF group, the regression model showed that PCS was the only significant predictor
415 variable for the onset of symptoms of ULNT1 (7.1% of variance). The No-NF group
416 obtained the same significant predictor variables as NF group, using submaximal pain
417 intensity reported in ULNT1 (PCS explained 12.8% of variance) and MPNFT (NDI
418 explained 9.8% of variance) as independent variables. No predictor variables were
419 found for any criterion variables in CG, nor for onset of symptoms of MPNFT in the
420 No-NF group.

421

422 **DISCUSSION**

423 The results of this study demonstrated that chronic nonspecific neck pain patients
424 with NF showed greater neural mechanosensitivity during neurodynamic testing than
425 those with No-NF. Patients with NF also reported greater pain intensity and greater
426 disability when compared to those with No-NF, but these differences were within the
427 limits of the MDC and could thus be explained by measurement error. Furthermore,
428 statistically significant differences were observed between the two groups with
429 chronic nonspecific neck pain versus CG in all variables, except when the No-NF
430 group was compared with CG for onset of symptoms of ULNT1.

431

432 Our results are consistent with two previous studies showing a complex presentation
433 of higher levels of pain, disability and hypersensitivity when NF is present in chronic
434 neck pain [13,22]. Our findings are consistent with our hypothesis that patients with
435 chronic nonspecific neck pain and NF will develop symptoms much earlier than
436 patients in the No-NF group in tests focused on increasing neural tension, indicating
437 greater mechanosensitivity in the NF group.

438

439 To our knowledge, no previous studies in the literature have evaluated differences in
440 the mechanosensitivity of the cervical region and median nerve of chronic nonspecific
441 neck pain patients with NF and those with No-NF; however, differences in
442 mechanosensitivity as determined by the ULNT1 have been observed between
443 patients with acute whiplash with and without NF [21]. In addition, a study conducted
444 by Beith et al. [58] reported increased mechanosensitivity in low back pain patients

445 with possible neuropathic origin when they received a passive straight leg raise test,
446 compared to patients whose back pain was of possible nociceptive origin.

447

448 Our study agrees with numerous reports that pain with NF is more intense and
449 produces greater disability than pain with No-NF; however, our outcomes did not
450 exceed the MCD and therefore should be taken with caution [58–62]. Nonetheless, no
451 differences were found between both types of pain for kinesiophobia and pain
452 catastrophizing. The evidence concerning psychosocial factors is contradictory. In
453 agreement with our results, some studies have demonstrated that patients with
454 neuropathic orofacial pain have similar levels of catastrophizing, anxiety, and
455 depression as those with non-neuropathic orofacial pain [63,64]. However, studies in
456 subjects with low back pain have found that anxiety and depression, both related to
457 pain catastrophizing [65,66], are significantly higher in patients with NF than in those
458 with No-NF [58,62]. These differences between regions are beyond our knowledge.
459 Reinforcing our results, numerous studies have reported that psychosocial adverse
460 effects caused by chronic pain are independent of their origin [64,67–69].

461

462 Statistically significant differences were observed when either the NF or No-NF
463 group was compared with the CG for all of the variables except the ULNT1 results
464 when the No-NF and CG groups were compared.

465

466 As mentioned previously, no significant difference was found in the range of motion
467 that triggered the onset of symptoms in the ULNT1 between patients with No-NF and
468 the healthy controls, although we observed an important trend toward significance. As
469 far as the authors know, there are no studies available to discuss this result. Other

470 authors have found differences in the ULNT1 results between patients with chronic
471 whiplash and healthy subjects [22]; thus, our observed lack of differences between the
472 No-NF group and CG could be explained by the fact that chronic whiplash condition
473 presents with NF [12,18]. Heightened neural mechanosensitivity in NF group at sites
474 outside and remote to the symptomatic site (neck region), could be suggestive of
475 central sensitization since there is large evidence that supports the presence of
476 generalized hypersensitivity of the somatosensory system in this condition [11,39,70–
477 72]. In addition, an increased response to the ULNT1 has been proposed as a sign of
478 central sensitization [73,74]. Thus, these findings suggest that the pain with NF might
479 be associated with central sensitization, whereas pain with No-NF might be only
480 peripheral sensitization. Consistent with this theory, other authors have demonstrated
481 higher probability of having signs of central sensitization in patients with pain with
482 NF [12,20,39,71,72,75].

483

484 In general, we must emphasize that the contribution of regression models as potential
485 predictors was small. Regression models showed that, for onset of symptoms of
486 ULNT1, a negative predictor in the NF group was kinesiophobia, whereas in the No-
487 NF group it was pain catastrophizing. Increased psychosocial factors are associated
488 with larger outcomes in pain and disability [76–79], which could explain this early
489 onset of symptoms. Regarding the onset of symptoms of MPNFT, only pain intensity
490 was a negative predictor for the NF group, and no predictor was found for the No-NF
491 group. Concerning the submaximal pain intensity reported by performing
492 neurodynamic tests, our findings showed that pain catastrophizing was a positive
493 predictor for ULNT1 in both groups, while for MPNFT the positive predictor was
494 NDI. Again, these results are supported by wide evidence that exhibits an important

495 link between psychosocial factors, disability, and pain [76–78,80]. It is important to
496 note that in CG, no correlations were found between physical-psychological variables
497 and those related to the neurodynamic tests, and therefore the CG had no predictor
498 variables. However, Beneciuk et al. [29] found that an increase in pain catastrophizing
499 was a predictor of an increased pain intensity perception when ULNT1 was
500 performed. Perhaps the difference between our results and those of Beneciuk lies in
501 that their sample had a much lower average age and was constituted of more males,
502 but really the authors do not know the exact reason for these differences.

503

504 **Study limitations**

505 This cross-sectional study had some limitations. Firstly, the assessor was unblinded to
506 the results, potentially compromising the validity of them. Thus, these findings should
507 be interpreted with caution. Secondly, it was a cross-sectional study so the results
508 cannot be used with predictive value [81]. Future studies with longitudinal designs to
509 check the trend of these associations are needed. Thirdly, the LANSS scale has been
510 validated to Spanish [82], but not S-LANSS. The unique difference between these
511 two scales is that the latter two items are performed by an examiner in the LANSS
512 scale, while in S-LANSS are performed by the patients themselves. In our opinion,
513 this fact should be considered, although we do not believe that was crucial for our
514 results. Another limitation was that although the S-LANSS scale is validated as a
515 screening tool for pain with NF [28], currently there is no “gold standard,” and this is
516 considered a potential risk for error [28,83].

517

518 **Clinical Implications**

519 Having the tools to identify clinical differences in patients with chronic nonspecific
520 neck pain will allow us to select the most effective interventions for each patient. Our
521 findings reflect a greater sensitization and a greater involvement of negative
522 psychosocial factors in chronic nonspecific neck pain patients with NF versus chronic
523 nonspecific neck pain patients with No-NF.

524

525 **CONCLUSIONS**

526 This study suggests that chronic nonspecific neck pain patients with NF have greater
527 neural mechanosensitivity, pain intensity, and neck disability than those with No-NF;
528 however, the differences for pain intensity and neck disability did not exceed the
529 MDC. Both chronic nonspecific neck pain groups showed statistically significant
530 differences when compared with CG for all outcomes, except between No-NF group
531 and CG for onset of symptoms of ULNT1. Future studies are needed to evaluate the
532 differences in the physical and psychological characteristics between pain with and
533 without NF to support these results.

534

535

536

537

538

539

540 REFERENCES

- 541 [1] Fejer R, Kyvik KO, Hartvigsen J. The prevalence of neck pain in the world
542 population: a systematic critical review of the literature. *Eur Spine J*
543 2006;15:834–48.
- 544 [2] Côté P, van der Velde G, Cassidy JD, et al. The burden and determinants of
545 neck pain in workers: results of the Bone and Joint Decade 2000-2010 Task
546 Force on Neck Pain and Its Associated Disorders. *J Manipulative Physiol Ther*
547 2009;32:S70–86.
- 548 [3] Martin BI, Deyo RA, Mirza SK, et al. Expenditures and health status among
549 adults with back and neck problems. *JAMA* 2008;299:656–64.
- 550 [4] Hogg-Johnson S, van der Velde G, Carroll LJ, et al. The burden and
551 determinants of neck pain in the general population: results of the Bone and
552 Joint Decade 2000-2010 Task Force on Neck Pain and Its Associated
553 Disorders. *J Manipulative Physiol Ther* 2009;32:S46–60.
- 554 [5] Carroll LJ, Hogg-Johnson S, Côté P, et al. Course and prognostic factors for
555 neck pain in workers: results of the Bone and Joint Decade 2000-2010 Task
556 Force on Neck Pain and Its Associated Disorders. *J Manipulative Physiol Ther*
557 2009;32:S108–16.
- 558 [6] Merskey H, Bogduk N. Part III: Pain Terms, A Current List with Definitions
559 and Notes on Usage. In: IASP Press, editor. *Classif. Chronic Pain*. 2nd ed.
560 Seattle, WA: IASP, Inc.; 1994, p. 209–14.
- 561 [7] Treede R-D, Jensen TS, Campbell JN, et al. Neuropathic pain: redefinition and
562 a grading system for clinical and research purposes. *Neurology* 2008;70:1630–
563 5.
- 564 [8] Leung L, Cahill CM. TNF-alpha and neuropathic pain--a review. *J*
565 *Neuroinflammation* 2010;7:27.
- 566 [9] Fishbain DA, Lewis JE, Cutler R, Cole B, Rosomoff HL, Rosomoff RS. Can
567 the neuropathic pain scale discriminate between non-neuropathic and
568 neuropathic pain? *Pain Med* 2008;9:149–60.
- 569 [10] Bennett GJ. Neuropathic pain: a crisis of definition? *Anesth Analg*
570 2003;97:619–20.
- 571 [11] Sterling M, Jull G, Vicenzino B, Kenardy J. Sensory hypersensitivity occurs
572 soon after whiplash injury and is associated with poor recovery. *Pain*
573 2003;104:509–17.
- 574 [12] Chien A, Eliav E, Sterling M. Hypoaesthesia occurs with sensory
575 hypersensitivity in chronic whiplash--further evidence of a neuropathic
576 condition. *Man Ther* 2009;14:138–46.

- 577 [13] Scott D, Jull G, Sterling M. Widespread sensory hypersensitivity is a feature of
578 chronic whiplash-associated disorder but not chronic idiopathic neck pain. *Clin*
579 *J Pain* 2005;21:175–81.
- 580 [14] Smith AD, Jull G, Schneider G, Frizzell B, Hooper RA, Sterling M. A
581 comparison of physical and psychological features of responders and non-
582 responders to cervical facet blocks in chronic whiplash. *BMC Musculoskelet*
583 *Disord* 2013;14:313.
- 584 [15] Sterling M. Differential development of sensory hypersensitivity and a measure
585 of spinal cord hyperexcitability following whiplash injury. *Pain* 2010;150:501–
586 6.
- 587 [16] Javanshir K, Ortega-Santiago R, Mohseni-Bandpei MA, Miangolarra-Page JC,
588 Fernández-de-Las-Peñas C. Exploration of somatosensory impairments in
589 subjects with mechanical idiopathic neck pain: a preliminary study. *J*
590 *Manipulative Physiol Ther* 2010;33:493–9.
- 591 [17] Johnston V, Jimmieson NL, Jull G, Souvlis T. Quantitative sensory measures
592 distinguish office workers with varying levels of neck pain and disability. *Pain*
593 2008;137:257–65.
- 594 [18] Chien A, Sterling M. Sensory hypoaesthesia is a feature of chronic whiplash
595 but not chronic idiopathic neck pain. *Man Ther* 2010;15:48–53.
- 596 [19] La Touche R, Fernández-de-Las-Peñas C, Fernández-Carnero J, Díaz-Parreño
597 S, Paris-Alemay A, Arendt-Nielsen L. Bilateral mechanical-pain sensitivity
598 over the trigeminal region in patients with chronic mechanical neck pain. *J Pain*
599 2010;11:256–63.
- 600 [20] Chien A, Eliav E, Sterling M. Whiplash (grade II) and cervical radiculopathy
601 share a similar sensory presentation: an investigation using quantitative sensory
602 testing. *Clin J Pain* 2008;24:595–603.
- 603 [21] Sterling M, Pedler A. A neuropathic pain component is common in acute
604 whiplash and associated with a more complex clinical presentation. *Man Ther*
605 2009;14:173–9.
- 606 [22] Ng TS, Pedler A, Vicenzino B, Sterling M. Less efficacious conditioned pain
607 modulation and sensory hypersensitivity in chronic whiplash-associated
608 disorders in Singapore. *Clin J Pain* 2014;30:436–42.
- 609 [23] Nee RJ, Butler D. Management of peripheral neuropathic pain: Integrating
610 neurobiology, neurodynamics, and clinical evidence. *Phys Ther Sport*
611 2006;7:36–49.
- 612 [24] Backonja M-M. Defining neuropathic pain. *Anesth Analg* 2003;97:785–90.
- 613 [25] Besson JM, Chaouch A. Peripheral and spinal mechanisms of nociception.
614 *Physiol Rev* 1987;67:67–186.

- 615 [26] Hansson P. Difficulties in stratifying neuropathic pain by mechanisms. *Eur J*
616 *Pain* 2003;7:353–7.
- 617 [27] Wall PD. Neuropathic pain and injured nerve: central mechanisms. *Br Med*
618 *Bull* 1991;47:631–43.
- 619 [28] Bennett MI, Smith BH, Torrance N, Potter J. The S-LANSS score for
620 identifying pain of predominantly neuropathic origin: validation for use in
621 clinical and postal research. *J Pain* 2005;6:149–58.
- 622 [29] Beneciuk JM, Bishop MD, George SZ. Pain catastrophizing predicts pain
623 intensity during a neurodynamic test for the median nerve in healthy
624 participants. *Man Ther* 2010;15:370–5.
- 625 [30] Deyo RA, Diehl AK. Measuring physical and psychosocial function in patients
626 with low-back pain. *Spine (Phila Pa 1976)* 1983;8:635–42.
- 627 [31] McCracken LM, Gross RT, Sorg PJ, Edmands TA. Prediction of pain in
628 patients with chronic low back pain: effects of inaccurate prediction and pain-
629 related anxiety. *Behav Res Ther* 1993;31:647–52.
- 630 [32] Coppieters MW, Alshami AM, Hodges PW. An experimental pain model to
631 investigate the specificity of the neurodynamic test for the median nerve in the
632 differential diagnosis of hand symptoms. *Arch Phys Med Rehabil*
633 2006;87:1412–7.
- 634 [33] Jaberzadeh S, Scutter S, Nazeran H. Mechanosensitivity of the median nerve
635 and mechanically produced motor responses during Upper Limb
636 Neurodynamic Test 1. *Physiotherapy* 2005;91:94–100.
- 637 [34] Kleinrensink GJ, Stoeckart R, Mulder PG, et al. Upper limb tension tests as
638 tools in the diagnosis of nerve and plexus lesions. Anatomical and
639 biomechanical aspects. *Clin Biomech* 2000;15:9–14.
- 640 [35] Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic
641 symptoms and signs. *Pain* 2001;92:147–57.
- 642 [36] Brislin W. Back-Translation for Cross-Cultural Research. *J Cross Cult Psychol*
643 1970;1:185–216.
- 644 [37] Butler D. *The sensitive nervous system*. Adelaide, Australia: Noigroup
645 Publications; 2000.
- 646 [38] Elvey RL. Physical evaluation of the peripheral nervous system in disorders of
647 pain and dysfunction. *J Hand Ther* 1997;10:122–9.
- 648 [39] Sterling M, Treleaven J, Edwards S, Jull G. Pressure pain thresholds in chronic
649 whiplash associated disorder: Further evidence of altered central pain
650 processing. *J Musculoskelet Pain* 2002;10:69–81.

- 651 [40] Ide M, Ide J, Yamaga M, Takagi K. Symptoms and signs of irritation of the
652 brachial plexus in whiplash injuries. *J Bone Joint Surg Br* 2001;83:226–9.
- 653 [41] Oliver GS, Rushton A. A study to explore the reliability and precision of intra
654 and inter-rater measures of ULNT1 on an asymptomatic population. *Man Ther*
655 2011;16:203–6.
- 656 [42] Coppieters M, Stappaerts K, Janssens K, Jull G. Reliability of detecting “onset
657 of pain” and “submaximal pain” during neural provocation testing of the upper
658 quadrant. *Physiother Res Int* 2002;7:146–56.
- 659 [43] Apelby-Albrecht M, Andersson L, Kleiva IW, Kvåle K, Skillgate E, Josephson
660 A. Concordance of upper limb neurodynamic tests with medical examination
661 and magnetic resonance imaging in patients with cervical radiculopathy: a
662 diagnostic cohort study. *J Manipulative Physiol Ther* 2013;36:626–32.
- 663 [44] Nee RJ, Jull GA, Vicenzino B, Coppieters MW. The validity of upper-limb
664 neurodynamic tests for detecting peripheral neuropathic pain. *J Orthop Sports
665 Phys Ther* 2012;42:413–24.
- 666 [45] Jensen MP, Turner JA, Romano JM, Fisher LD. Comparative reliability and
667 validity of chronic pain intensity measures. *Pain* 1999;83:157–62.
- 668 [46] Katz J, Melzack R. Measurement of pain. *Surg Clin North Am* 1999;79:231–
669 52.
- 670 [47] Emshoff R, Bertram S, Emshoff I. Clinically important difference thresholds of
671 the visual analog scale: a conceptual model for identifying meaningful
672 intraindividual changes for pain intensity. *Pain* 2011;152:2277–82.
- 673 [48] MacDermid JC, Walton DM, Avery S, et al. Measurement properties of the
674 neck disability index: a systematic review. *J Orthop Sports Phys Ther*
675 2009;39:400–17.
- 676 [49] Vernon H. The Neck Disability Index: state-of-the-art, 1991-2008. *J
677 Manipulative Physiol Ther* 2008;31:491–502.
- 678 [50] Andrade Ortega JA, Delgado Martínez AD, Almécija Ruiz R. Validation of the
679 Spanish version of the Neck Disability Index. *Spine (Phila Pa 1976)*
680 2010;35:E114–8.
- 681 [51] Gómez-Pérez L, López-Martínez AE, Ruiz-Párraga GT. Psychometric
682 Properties of the Spanish Version of the Tampa Scale for Kinesiophobia
683 (TSK). *J Pain* 2011;12:425–35.
- 684 [52] Hapidou EG, O’Brien MA, Pierrynowski MR, de Las Heras E, Patel M, Patla
685 T. Fear and Avoidance of Movement in People with Chronic Pain:
686 Psychometric Properties of the 11-Item Tampa Scale for Kinesiophobia (TSK-
687 11). *Physiother Can* 2012;64:235–41.

- 688 [53] García Campayo J, Rodero B, Alda M, Sobradie N, Montero J, Moreno S.
689 [Validation of the Spanish version of the Pain Catastrophizing Scale in
690 fibromyalgia]. *Med Clin (Barc)* 2008;131:487–92.
- 691 [54] Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical
692 power analysis program for the social, behavioral, and biomedical sciences.
693 *Behav Res Methods* 2007;39:175–91.
- 694 [55] Mouri H. Log-normal distribution from a process that is not multiplicative but
695 is additive. *Phys Rev E* 2013;88:042124.
- 696 [56] Nixon RM, Wonderling D, Grieve RD. Non-parametric methods for cost-
697 effectiveness analysis: the central limit theorem and the bootstrap compared.
698 *Health Econ* 2010;19:316–33.
- 699 [57] Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR. A simulation
700 study of the number of events per variable in logistic regression analysis. *J Clin*
701 *Epidemiol* 1996;49:1373–9.
- 702 [58] Beith ID, Kemp A, Kenyon J, Prout M, Chestnut TJ. Identifying neuropathic
703 back and leg pain: a cross-sectional study. *Pain* 2011;152:1511–6.
- 704 [59] Berger A, Toelle T, Sadosky A, Dukes E, Edelsberg J, Oster G. Clinical and
705 economic characteristics of patients with painful neuropathic disorders in
706 Germany. *Pain Pract* 2009;9:8–17.
- 707 [60] Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C. Prevalence of
708 chronic pain with neuropathic characteristics in the general population. *Pain*
709 2008;136:380–7.
- 710 [61] Smith BH, Torrance N, Bennett MI, Lee AJ. Health and quality of life
711 associated with chronic pain of predominantly neuropathic origin in the
712 community. *Clin J Pain* 2007;23:143–9.
- 713 [62] Freynhagen R, Baron R, Gockel U, Tölle TR. painDETECT: a new screening
714 questionnaire to identify neuropathic components in patients with back pain.
715 *Curr Med Res Opin* 2006;22:1911–20.
- 716 [63] Gustin SM, Wilcox SL, Peck CC, Murray GM, Henderson LA. Similarity of
717 suffering: equivalence of psychological and psychosocial factors in neuropathic
718 and non-neuropathic orofacial pain patients. *Pain* 2011;152:825–32.
- 719 [64] Castro AR de, Siqueira SRDT de, Perissinotti DMN, Siqueira JTT de.
720 Psychological evaluation and cope with trigeminal neuralgia and
721 temporomandibular disorder. *Arq Neuropsiquiatr* 2008;66:716–9.
- 722 [65] Garnefski N, Kraaij V. Cognitive coping and goal adjustment are associated
723 with symptoms of depression and anxiety in people with acquired hearing loss.
724 *Int J Audiol* 2012;51:545–50.

- 725 [66] Kraaij V, Garnefski N, Schroevers MJ, Weijmer J, Helmerhorst F. Cognitive
726 coping, goal adjustment, and depressive and anxiety symptoms in people
727 undergoing infertility treatment: a prospective study. *J Health Psychol*
728 2010;15:876–86.
- 729 [67] Daniel HC, Narewska J, Serpell M, Hoggart B, Johnson R, Rice ASC.
730 Comparison of psychological and physical function in neuropathic pain and
731 nociceptive pain: implications for cognitive behavioral pain management
732 programs. *Eur J Pain* 2008;12:731–41.
- 733 [68] Haythornthwaite JA, Benrud-Larson LM. Psychological aspects of neuropathic
734 pain. *Clin J Pain* 2000;16:S101–5.
- 735 [69] Hummel M, Lu P, Cummons TA, Whiteside GT. The persistence of a long-
736 term negative affective state following the induction of either acute or chronic
737 pain. *Pain* 2008;140:436–45.
- 738 [70] Sterling M, Jull G, Kenardy J. Physical and psychological factors maintain
739 long-term predictive capacity post-whiplash injury. *Pain* 2006;122:102–8.
- 740 [71] Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Giani C, Zbinden AM,
741 Radanov BP. Central hypersensitivity in chronic pain after whiplash injury.
742 *Clin J Pain* 2001;17:306–15.
- 743 [72] Herren-Gerber R, Weiss S, Arendt-Nielsen L, et al. Modulation of central
744 hypersensitivity by nociceptive input in chronic pain after whiplash injury. *Pain*
745 *Med* 2004;5:366–76.
- 746 [73] Nijs J, Van Houdenhove B, Oostendorp RAB. Recognition of central
747 sensitization in patients with musculoskeletal pain: Application of pain
748 neurophysiology in manual therapy practice. *Man Ther* 2010;15:135–41.
- 749 [74] Sterling M, Kenardy J. Physical and psychological aspects of whiplash:
750 Important considerations for primary care assessment. *Man Ther* 2008;13:93–
751 102.
- 752 [75] Hochman JR, Davis AM, Elkayam J, Gagliese L, Hawker GA. Neuropathic
753 pain symptoms on the modified painDETECT correlate with signs of central
754 sensitization in knee osteoarthritis. *Osteoarthritis Cartilage* 2013;21:1236–42.
- 755 [76] Saavedra-Hernández M, Castro-Sánchez AM, Cuesta-Vargas AI, Cleland JA,
756 Fernández-de-las-Peñas C, Arroyo-Morales M. The contribution of previous
757 episodes of pain, pain intensity, physical impairment, and pain-related fear to
758 disability in patients with chronic mechanical neck pain. *Am J Phys Med*
759 *Rehabil* 2012;91:1070–6.
- 760 [77] Bean DJ, Johnson MH, Kydd RR. Relationships Between Psychological
761 Factors, Pain and Disability in Complex Regional Pain Syndrome and Low
762 Back Pain. *Clin J Pain* 2013;30:647–53.

- 763 [78] Thompson DP, Urmston M, Oldham JA, Woby SR. The association between
764 cognitive factors, pain and disability in patients with idiopathic chronic neck
765 pain. *Disabil Rehabil* 2010;32:1758–67.
- 766 [79] Velly AM, Look JO, Carlson C, et al. The effect of catastrophizing and
767 depression on chronic pain--a prospective cohort study of temporomandibular
768 muscle and joint pain disorders. *Pain* 2011;152:2377–83.
- 769 [80] Doménech J, Sanchis-Alfonso V, Espejo B. Changes in catastrophizing and
770 kinesiophobia are predictive of changes in disability and pain after treatment in
771 patients with anterior knee pain. *Knee Surg Sports Traumatol Arthrosc*
772 2014;22:2295–300.
- 773 [81] Haro JM, Kontodimas S, Negrin MA, Ratcliffe M, Suarez D, Windmeijer F.
774 Methodological aspects in the assessment of treatment effects in observational
775 health outcomes studies. *Appl Health Econ Health Policy* 2006;5:11–25.
- 776 [82] Pérez C, Gálvez R, Insausti J, Bennett M, Ruiz M, Rejas J. [Linguistic
777 adaptation and Spanish validation of the LANSS (Leeds Assessment of
778 Neuropathic Symptoms and Signs) scale for the diagnosis of neuropathic pain].
779 *Med Clin (Barc)* 2006;127:485–91.
- 780 [83] Hardy J, Quinn S, Fazekas B, Agar M, Currow D. Can the LANSS scale be
781 used to classify pain in chronic cancer pain trials? *Support Care Cancer*
782 2013;21:3387–91.
- 783

Figure 1. Neurodynamic tests.

NEURODYNAMIC TESTS



a. Upper Limb Neural Test 1.



b. Modified Passive Neck Flexion Test.

Table 1. Demographic characteristics and neck pain duration of participants. Values are mean \pm SD and n (%).

	NF (n = 49)	No-NF (n = 50)	CG (n = 48)	P value of independent samples ANOVA or χ^2 test
Age years	42.38 \pm 14.26	44.76 \pm 14.66	43.64 \pm 11.09	0.683*
Gender (female)	41 (83.7)	37 (74)	33 (68.8)	0,222†
Height (cm)	164.65 \pm 8.51	164.82 \pm 9.34	168.5 \pm 8.75	0.061*
Weight (kg)	65.73 \pm 11.79	65.57 \pm 12.5	65.57 \pm 12.98	0.997*
Neck pain duration				
3 to 6mo	3 (6.1)	8 (15.7)	-	0.461†
7 to 12mo	3 (6.1)	5 (9.8)	-	0.161†
13 and 36mo	11 (22.5)	8 (15.7)	-	0.172†
More than 36mo	32 (65.3)	30 (58.8)	-	0.153†

Abbreviations: NF, Pain with Neuropathic Features; No-NF, Pain without Neuropathic Features; CG, Control Group; ANOVA, Analysis Of Variance.

* Independent-samples ANOVA.

† χ^2 tests.

Table 2. Between group comparisons.

	Mean \pm SD			Mean difference (95% CI); a) NF vs. No-NF b) NF vs. CG c) No-NF vs. CG
	NF	No-NF	CG	
OS-ULNT1	62.74 \pm 23.14	77.84 \pm 15.05	86 \pm 8.06	a) -15.11 (-23.19 to -7.03) † b) -23.27 (-31.51 to -15.02) † c) -8.16 (-16.32 to 0.01)
SP-ULNT1	46 \pm 22.95	37.18 \pm 28.13	14.81 \pm 17.94	a) 8.82 (-2.57 to 20.22) b) 31.19 (19.56 to 42.82) † c) 22.38 (10.85 to 33.89) †
OS-MPNFT	53.78 \pm 11.83	60.35 \pm 9.8	70.04 \pm 7.24	a) -6.58 (-11.54 to -1.62) † b) -16.28 (-21.32 to -11.22) † c) -9.69 (-14.44 to -4.94) †
SP-MPNFT	45.53 \pm 15.31	48.35 \pm 18.98	4.13 \pm 8.84	a) -2.83 (-10.55 to 4.9) b) 41.4 (33.53 to 49.27) † c) 44.23 (36.83 to 51.62) †
VAS	59.96 \pm 11.93	52.84 \pm 14.44	-	a) 7.12 (1.81 to 12.42) † b) - c) -
NDI	16.24 \pm 4.79	12.53 \pm 5.07	0.66 \pm 1.01	a) 3.72 (1.72 to 5.71) † b) 15.56 (13.55 to 17.62) † c) 11.87 (9.86 to 13.88) †
TSK-11	30.84 \pm 6.09	29.29 \pm 7.62	20.66 \pm 6.42	a) 1.54 (-1.73 to 4.82) b) 10.18 (6.83 to 13.52) † c) 8.64 (5.32 to 11.95) †
PCS	16.45 \pm 9.56	13.57 \pm 9.07	4.55 \pm 4.43	a) 2.88 (-1.04 to 6.8) b) 11.9 (7.9 to 15.89) † c) 9.02 (5.06 to 12.97) †

Abbreviations: NF, Pain with Neuropathic Features; No-NF, Pain without Neuropathic Features; CG, Control Group; CI, Confidence interval; OS-ULNT1, Onset of Symptoms-Upper Limb Neural Test 1; SP-ULNT1, Submaximal Pain-ULNT1; OS-MPNFT, Onset of Symptoms-Modified Passive Neck Flexion Test-Range Of Motion; SP-MPNFT, Submaximal Pain-Modified Passive Neck Flexion Test; VAS, Visual Analogue Scale; NDI, Neck Disability Index; TSK-11, Tampa Scale of Kinesiophobia-11; PCS, Pain Catastrophizing Scale.

† P<0.01.

Table 3. Pearson correlation coefficient for all outcomes in each group.

Group		SP-ULNT1	OS-MPNFT	SP-MPNFT	VAS	NDI	TSK-11	PCS
NF	OS-ULNT1	-0.733†	0.586†	-0.278	-0.371†	-0.212	-0.455†	-0.439†
No-NF		-0.545†	0.392†	-0.198	0.129	-0.228	-0.058	-0.299*
CG		-0.617†	-0.153	-0.118	-	0.102	0.082	-0.136
NF	SP-ULNT1		-0.404†	0.493†	0.298*	0.191	0.386†	0.524†
No-NF			-0.079	0.601†	0.126	0.356*	0.224	0.382†
CG			-0.017	0.156	-	0.124	0.053	0.097
NF	OS-MPNFT			-0.407†	-0.547†	-0.330*	-0.218	-0.157
No-NF				0.125	0.081	0.004	-0.095	-0.272
CG				-0.113	-	0.008	0.103	0.129
NF	SP-MPNFT				0.093	0.349*	0.078	0.187
No-NF					0.251	0.341*	0.018	-0.009
CG					-	0.162	-0.054	-0.04
NF	VAS					0.176	0.306*	0.387†
No-NF						0.224	0.342*	0.236
CG						-	-	-
NF	NDI						0.229	0.455†
No-NF							0.455†	0.425†
CG							0.069	-0.006
NF	TSK-11							0.519†
No-NF								0.509†
CG								0.612†

Abbreviations: NF, Pain with Neuropathic Features; No-NF, Pain without Neuropathic Features; CG, Control Group; OS-ULNT1, Onset of Symptoms-Upper Limb Neural Test 1; SP-ULNT1, Submaximal Pain-Upper Limb Neural Test 1; OS-MPNFT, Onset of Symptoms-Modified Passive Neck Flexion Test; SP-MPNFT, Submaximal Pain-Modified Passive Neck Flexion Test; VAS, Visual Analogue Scale; NDI, Neck Disability Index; TSK-11, Tampa Scale of Kinesiophobia-11; PCS, Pain Catastrophizing Scale.

* P<0.05.

† P<0.01.

Table 4. Regression model for onset of symptoms of both neurodynamic tests in each chronic neck pain group.

Criterion variable: OS-ULNT1					
Group					
NF	Overall model				
	$R^2 = 0.207$ $\text{Adjusted } R^2 = 0.190$ $F = 12.247$				
	Predictor variables	Regression coefficient (B)	Standardized coefficient (β)	P value	VIF
	TSK-11	-1.727	-0.455	0.001	1.00
	Excluded variables				
	VAS	-	-0.256	0.059	1.103
	NDI	-	-0.113	0.401	1.056
	PCS	-	-0.278	0.067	1.368
No-NF	Overall model				
	$R^2 = 0.089$ $\text{Adjusted } R^2 = 0.071$ $F = 4.811$				
	Predictor variables	Regression coefficient (B)	Standardized coefficient (β)	P value	VIF
	PCS	-0.496	-0.299	0.033	1.00
	Excluded variables				
	VAS	-	0.212	0.133	1.059
	NDI	-	-0.123	0.418	1.221
	TSK-11	-	0.127	0.428	1.350
Criterion variable: OS-MPNFT					
Group					
NF	Overall model				
	$R^2 = 0.299$ $\text{Adjusted } R^2 = 0.280$ $F = 16.191$				
	Predictor Variables	Regression coefficient (B)	Standardized coefficient (β)	P value	VIF
	VAS	-5.485	-0.547	<0.001	1.00
	Excluded Variables				
	NDI	-	-0.223	0.109	1.048
	TSK-11	-	-0.040	0.784	1.124
	PCS	-	0.131	0.401	1.289

Abbreviations: VIF, variance inflation factor; NF, Pain with Neuropathic Features; No-NF, Pain without Neuropathic Features; OS-ULNT1, Onset of Symptoms-Upper Limb Neural Test 1; OS-MPNFT, Onset of Symptoms-Modified Passive Neck Flexion Test-Range Of Motion; VAS, Visual Analogue Scale; NDI, Neck Disability Index; TSK-11, Tampa Scale of Kinesiophobia-11; PCS, Pain Catastrophizing Scale.

Table 5. Regression model for submaximal pain intensity reported in both neurodynamic tests in each chronic neck pain group.

Criterion variable: SP-ULNT1					
Group					
NF	Overall model				
	$R^2 = 0.274$ $\text{Adjusted } R^2 = 0.259$ $F = 17.757$				
	Predictor variables	Regression coefficient (B)	Standardized coefficient (β)	P value	VIF
	PCS	0.126	0.524	<0.001	1.00
	Excluded variables				
	VAS	-	0.112	0.413	1.176
NDI	-	-0.060	0.671	1.261	
TSK-11	-	0.157	0.284	1.368	
No-NF	Overall model				
	$R^2 = 0.146$ $\text{Adjusted } R^2 = 0.128$ $F = 8.366$				
	Predictor Variables	Regression coefficient (B)	Standardized coefficient (β)	P value	VIF
	PCS	0.118	0.382	0.006	1.00
	Excluded variables				
	VAS	-	0.038	0.781	1.059
NDI	-	0.236	0.106	1.221	
TSK-11	-	0.040	0.796	1.350	
Criterion variable: SP-MPNFT					
Group					
NF	Overall model				
	$R^2 = 0.122$ $\text{Adjusted } R^2 = 0.098$ $F = 5.256$				
	Variables	Regression coefficient (B)	Standardized coefficient (β)	P value	VIF
	NDI	0.104	0.349	0.027	1.00
	Excluded variables				
	VAS	-	0.020	0.900	1.048
TSK-11	-	-0.004	0.978	1.059	
PCS	-	0.014	0.937	1.344	
No-NF	Overall model				
	$R^2 = 0.116$ $\text{Adjusted } R^2 = 0.098$ $F = 6.461$				
	Variables	Regression coefficient (B)	Standardized coefficient (β)	P value	VIF
	NDI	0.128	0.341	0.014	1.00
	Excluded variables				
	VAS	-	0.184	0.185	1.053
TSK-11	-	-0.172	0.257	1.260	
PCS	-	-0.188	0.209	1.221	

Abbreviations: VIF, variance inflation factor; NF, Pain with Neuropathic Features; No-NF, Pain without Neuropathic Features; SP-ULNT1, Submaximal Pain-Upper Limb Neural Test 1; SP-MPNFT, Submaximal Pain-Modified Passive Neck Flexion Test; VAS, Visual Analogue Scale; NDI, Neck Disability Index; TSK-11, Tampa Scale of Kinesiop